How has NeoGenomics's indefinite- lived intangible impairment changed year-over-year?

NeoGenomics's indefinite- lived intangible impairment decreased by 6.8% year-over-year, from $498.8M to $464.83M.

NeoGenomics NEO Indefinite- lived intangible impairment

Indefinite- lived intangible impairment at other companies

Labcorp HoldingsLH

——

Tempus AI, Inc.TEM

——

Agilent TechnologiesA

——

CareDxCDNA

——

VeracyteVCYT

——

Bio-Rad LaboratoriesBIO

——

Other financials

Income statement

See full

Revenue$186.7M+11.1%

Gross profit$80.9M+10.4%

Operating income-$18.2M+34.4%

Net income-$17.1M+34.0%

EPS (diluted)-$0.13+35.0%

Balance sheet

See full

Cash & equivalents$146.1M-57.8%

Total debt$66.3M+5.3%

Total equity$828.8M-6.7%

Total assets$1.3B-15.9%

Cash flow

See full

Operating cash flow-$8.1M+67.9%

CapEx$5.0M+11.1%

Free cash flow-$13.1M+56.0%

Valuation

See full

Market cap$1.68B+86.5%

Enterprise value$1.6B+159%

P/S2.3×+0.9×

Profitability

See full

Gross margin43.2%-1.1pp

Operating margin-14.2%+1.1pp

Net margin-13.3%+2.4pp

FCF margin-4.9%—

Returns & leverage

See full

Return on equity-11.6%+6.2pp

Debt / equity0.1×0.0×

Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsGrossExcludingGoodwill.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's indefinite- lived intangible impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NeoGenomics's indefinite- lived intangible impairment?: NeoGenomics (NEO) reported indefinite- lived intangible impairment of $464.83M in Q1 2026.
How has NeoGenomics's indefinite- lived intangible impairment changed year-over-year?: NeoGenomics's indefinite- lived intangible impairment decreased by 6.8% year-over-year, from $498.8M to $464.83M.